Improvement in QoL

78^%	reduction in DLQI score with Xolair^® 300 mg vs baseline at 12 weeks*^1,2

Improvement in Angiodema-free days

Higher proportion of angioedema-free days
95.5% mean proportion of
angioedema-free days^*‡1

Simple dosing schedule

Xolair^® is administered by
subcutaneous injection, using a pre-filled syringe^‡3

Find out more

Well tolerated

Xolair^® was well tolerated
in over 700 patients
in the CSU phase III
clinical program³

Find out more

Model is a hypothetical patient profile, for illustrative purposes only

*Data from ASTERIA II; two other phase III studies (ASTERIA I and GLACIAL) were also conducted to assess efficacy and safety of Xolair® in inadequately controlled CSU patients

^**Xolair® is also available as a lyophilized formulation

^†Xolair® 300mg vs. baseline at 12 weeks; p<0.001 vs placebo. DLQI: Dermatology Life Quality Index.

^‡From weeks 4—12 with Xolair® 300 mg vs. placebo (89.2%); p<0.001.

References: 1. Maurer M, et al. N Engl J Med 2013;368:924-935. 2. Casale T, et al. Allergy 2014;69(Suppl 99). Abstr 1662. 3. Xolair® Summary of Product Characteristics 2016

NP4 code: GLDEIM/IGE025E/0181